Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
VisualAbstract: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | 2 Minute Medicine
JCM | Free Full-Text | Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study | HTML
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer | BioSpace
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer - AstraZeneca
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian... | Download Scientific Diagram
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy - European Journal of Cancer
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial | International Journal of Gynecologic Cancer
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
Final Overall Survival Analysis From SOLO2 in Ovarian Cancer - The ASCO Post
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
Olaparib maintenance confers durable PFS benefit in advanced BRCA -mutated ovarian cancer
Olaparib for Metastatic Breast Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
Progression-free survival (PFS) and overall survival (OS) following... | Download Scientific Diagram
PARP inhibitors in ovarian cancer - Cancer Treatment Reviews
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
SOLO-1 Phase 3 Trial Demonstrates LYNPARZA® (olaparib) Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 Percent in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer | Business Wire
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models | Nature Communications
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
